sauristolactam

lactam of 10-aminomethyl-3-hydroxy-4-methoxyphenanthrene-1-carboxylic acid isolated from Saururus cernuus; structure given in first source

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

1.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/01/2010 - "The goal of this study was to study whether KO-202125 (KO), a sauristolactam derivative in KB human oral squamous carcinoma cells, inhibits the activity of COX-2 enzyme and induces apoptotic cell death. " 01/01/2010 - "KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression."
2.	Neoplasms (Cancer) 03/01/2011 - "The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer."
3.	Breast Neoplasms (Breast Cancer) 03/01/2011 - "The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer."

1.	KO 202125
2.	Enzymes
3.	ErbB Receptors (EGF Receptor)
4.	Cyclooxygenase 2 (Cyclooxygenase-2)